MRNS News and Press, Marinus Pharmaceuticals Inc. From 11/07/23

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...

Marinus Pharmaceuticals Inc. (MRNS) is expected to report $-0.67 for Q3 2023

2023-11-06 11:30:48 ET More on Marinus Pharmaceuticals Evaluating Marinus: Ztalmy's Growth And Upcoming Trial Insights Marinus stock jumps 11% on financial, pipeline updates Marinus downgraded by Oppenheimer on concerns over seizure asset trial For further de...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023. The Company ...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the 2023 Can...

2023-09-20 17:12:25 ET Gainers: Marinus Pharmaceuticals ( NASDAQ: MRNS ) +8% . Complete Solaria ( CSLR ) +5% . Arhaus ( ARHS ) +5% . COMPASS Pathways ( CMPS ) +5% . Quantum-Si  ( QSI ) +5% . Losers: Vahanna Tech ...

2023-09-19 12:36:23 ET More on Marinus Pharmaceuticals Evaluating Marinus: Ztalmy's Growth And Upcoming Trial Insights Marinus: Transforming The Seizure Market With Ganaxolone (Rating Upgrade) Marinus downgraded by Oppenheimer on concerns over seizure asset trial ...

RAISE trial enrollment trends have returned to anticipated levels; on track for topline data in the first quarter of 2024, assuming pre-defined stopping criteria for interim analysis are met Continued execution of commercial launch of ZTALMY ® (ganaxolone) with estimated net prod...

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the speakers for its upcoming Investor & Analyst Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern Tim...

2023-09-04 14:38:18 ET Summary Marinus Pharmaceuticals received FDA approval for Ztalmy to treat seizures; aims to broaden its application. Marinus has strong financial standing with a cash runway until late 2024; ongoing trials on Ztalmy show potential. Recommendation: Mainta...